Associations, Outcomes and Genomics of GB Virus C, Hepatitis C Virus and Human Immunodeficiency Virus Infection

This study has been terminated.
Sponsor:
Information provided by:
Bayside Health
ClinicalTrials.gov Identifier:
NCT00164060
First received: September 13, 2005
Last updated: December 3, 2013
Last verified: September 2005
  Purpose

The purpose of this study is to examine the effect of GB virus C (GBV-C) on the natural history of chronic hepatitis C virus (HCV) infection in subjects co-infected with HIV and HCV. The other aspect of the study is to assess the effect of GBV-C on the severity of liver disease due to chronic hepatitis C in subjects co-infected with HIV and HCV. This will be done by determining the point prevalence of co-infection retrospectively then following that cohort prospectively. In addition, further individuals will be recruited in a prospective manner.


Condition
Hepatitis C
HIV Infections

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: Associations, Outcomes and Genomics of GB Virus C, Hepatitis C Virus and Human Immunodeficiency Virus Infection

Resource links provided by NLM:


Further study details as provided by Bayside Health:

Enrollment: 158
Study Start Date: February 2004
Study Completion Date: May 2007
Primary Completion Date: May 2007 (Final data collection date for primary outcome measure)
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Sera available and appropriate for testing, including serial sera over a period of time (retrospective analysis)
  2. HIV serology positive.
  3. Unequivocal HCV antibody positive or HCV RNA positive.

Exclusion Criteria:

  1. Those without sera available.
  2. Those unwilling to give informed consent.
  3. Persons with hepatitis B virus infection, as defined by the presence of hepatitis B surface antigen and/or hepatitis B virus DNA positive.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00164060

Locations
Australia, Victoria
Alfred Hospital
Melbourne, Victoria, Australia, 3181
Sponsors and Collaborators
Bayside Health
Investigators
Principal Investigator: Mark D Berzsenyi, MBBS Alfred Hospital/Bayside Health
Study Director: Stuart R Roberts, MBBS Alfred Hospital/Bayside Health
  More Information

Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00164060     History of Changes
Other Study ID Numbers: 35/04
Study First Received: September 13, 2005
Last Updated: December 3, 2013
Health Authority: Australia: Human Research Ethics Committee

Keywords provided by Bayside Health:
HCV
HIV co-infection

Additional relevant MeSH terms:
Acquired Immunodeficiency Syndrome
HIV Infections
Hepatitis
Hepatitis A
Hepatitis C
Immunologic Deficiency Syndromes
Virus Diseases
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Slow Virus Diseases
Immune System Diseases
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Enterovirus Infections
Picornaviridae Infections
Flaviviridae Infections

ClinicalTrials.gov processed this record on August 25, 2014